Details of the Drug

General Information of Drug (ID: DMXEJZO)

Drug Name
LX1001
Synonyms AAVrh.10hAPOE2
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 1/2 [1]
Drug Type
Gene therapy
Cross-matching ID
TTD ID
D6UEI3

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Apolipoprotein E (APOE) TTKS9CB APOE_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03634007) A 52-Week, Multicenter, Phase 1/2 Open-label Study to Evaluate the Safety of LX1001 in Participants With APOE4 Homozygote Alzheimer's Disease. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Lexeo Therapeutics